HeartSciences Inc. (HSCS) · Nov 19, 2026 · Share issuance
$3.08M ATM capacity — Current prospectus limit: $3,077,649
HeartSciences’ new financing agreement offers a $50M ATM headline, but Form S-3 limits current sales to $3.08M as the Fortitude merger nears.
HeartSciences is a cash-starved cardiac-diagnostics company attempting to transform into the public vehicle for Fortitude’s Zcash-focused mining platform; its July 31, 2026 10-Q showed only $29,906 of cash and cash equivalents, while the merger still required shareholder approval.
The filing creates a financing channel, but not $50 million of immediate funding. HeartSciences signed an equity distribution agreement allowing sales of up to $50 million of common stock. However, the current Form S-3 shareholder-float limitation caps the prospectus supplement at only $3,077,649. 〔0〕
| Key term | Filing figure | Comparison |
|---|---|---|
| ATM authorization (EDA) | $50.0M | — |
| Current S-3 sale limit | $3.077649M | $50.0M authorization |
| Sales commission | 2.5% | 2.0% thereafter |
| Legal-fee reimbursement | $15,000 + $5,000/bringdown | — |
This is a necessary liquidity option, but it brings dilution without guaranteed proceeds. Maxim is acting as an agent and is not required to buy the shares itself, so the agreement does not ensure that HeartSciences raises the available amount. 〔1〕 For a company with minimal cash and a merger-dependent business plan, the facility improves near-term funding flexibility, but the immediate capacity is small and any sales would dilute existing holders.
The financing also reinforces that the Fortitude transaction remains unfinished. The merger was already publicly announced and the definitive proxy statement had been filed, with the shareholder meeting scheduled for November 19, 2026; this 8-K does not advance closing terms or confirm completion.
Bottom line: This is a modestly negative financing update: HeartSciences gains a needed cash-raising mechanism, but the usable amount is only about $3.08 million and comes with potential dilution while the Fortitude merger is still pending.
Shareholder vote on Fortitude merger, November 19
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!